{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:58:56Z","timestamp":1791197936248,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10935"],"award-info":[{"award-number":["24K10935"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K19236"],"award-info":[{"award-number":["25K19236"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12185-026-04231-0","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:55:31Z","timestamp":1779983731000},"page":"538-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Repeated short-interval administration of efanesoctocog alfa is not associated with increased global coagulation potential in hemophilia A mice"],"prefix":"10.1007","volume":"124","author":[{"given":"Yuki","family":"Kawasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5422-2782","authenticated-orcid":false,"given":"Yuto","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"4231_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5435\/00124635-200407000-00004","volume":"12","author":"JV Luck Jr","year":"2004","unstructured":"Luck JV Jr, Silva M, Rodriguez-Merchan EC, Ghalambor N, Zahiri CA, Finn RS. Hemophilic arthropathy. J Am Acad Orthop Surg. 2004;12:234\u201345.","journal-title":"J Am Acad Orthop Surg"},{"key":"4231_CR2","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1055\/s-0037-1615621","volume":"85","author":"GC White 2nd","year":"2001","unstructured":"White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.","journal-title":"Thromb Haemost"},{"key":"4231_CR3","doi-asserted-by":"crossref","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1\u201347.","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"4231_CR4","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1182\/bloodadvances.2023011780","volume":"8","author":"FM Horling","year":"2024","unstructured":"Horling FM, Reipert BM, Allacher P, Engl W, Pan L, Tangada S. Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A. Blood Adv. 2024;8:2726\u201339.","journal-title":"Blood Adv"},{"key":"4231_CR5","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1182\/blood.2019001292","volume":"135","author":"E Seth Chhabra","year":"2020","unstructured":"Seth Chhabra E, Liu T, Kulman J, Patarroyo-White S, Yang B, Lu Q, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood. 2020;135:1484\u201396.","journal-title":"Blood"},{"key":"4231_CR6","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJMoa2002699","volume":"383","author":"BA Konkle","year":"2020","unstructured":"Konkle BA, Shapiro AD, Quon DV, Staber JM, Kulkarni R, Ragni MV, et al. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A. N Engl J Med. 2020;383:1018\u201327.","journal-title":"N Engl J Med"},{"key":"4231_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkle BA, Oldenburg J, et al. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. N Engl J Med. 2023;388:310\u20138.","journal-title":"N Engl J Med"},{"key":"4231_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1056\/NEJM200008173430702","volume":"343","author":"PA Kyrle","year":"2000","unstructured":"Kyrle PA, Minar E, Hirschl M, Bialonczyk C, Stain M, Schneider B, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med. 2000;343:457\u201362.","journal-title":"N Engl J Med"},{"key":"4231_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/j.1365-2257.2004.00605.x","volume":"26","author":"M Okuda","year":"2004","unstructured":"Okuda M, Yamamoto Y. Usefulness of synthetic phospholipids in measurement of activated partial thromboplastin time: a new preparation procedure to reduce batch difference. Clin Lab Haematol. 2004;26:215\u201323.","journal-title":"Clin Lab Haematol"},{"key":"4231_CR10","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1182\/bloodadvances.2023012391","volume":"8","author":"Y Nakajima","year":"2024","unstructured":"Nakajima Y, Oda A, Baatartsogt N, Kashiwakura Y, Ohmori T, Nogami K. The combination of Asp519Val\/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential. Blood Adv. 2024;8:3929\u201340.","journal-title":"Blood Adv"},{"key":"4231_CR11","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/bloodadvances.2019000999","volume":"4","author":"S Pestel","year":"2020","unstructured":"Pestel S, Beltz HW, Claar P, Lind H, Mischnik M, Raquet E, et al. FVIII half-life extension by coadministration of a D\u2019D3 albumin fusion protein in mice, rabbits, rats, and monkeys. Blood Adv. 2020;4:1870\u201380.","journal-title":"Blood Adv"},{"key":"4231_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102479","volume":"8","author":"Y Nakajima","year":"2024","unstructured":"Nakajima Y, Osuna M, Mizumachi K, Shimonishi N, Furukawa S, Ogiwara K, et al. Activated protein C resistance in the copresence of emicizumab and activated prothrombin complex concentrates. Res Pract Thromb Haemost. 2024;8:102479.","journal-title":"Res Pract Thromb Haemost"},{"key":"4231_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/hae.70087","volume":"31","author":"Y Kawasaki","year":"2025","unstructured":"Kawasaki Y, Nakajima Y, Nogami K. Coagulation Potential in Haemostatic Agents Concomitant With Low Concentration of Emicizumab Under Severe Haemophilia A State. Haemophilia. 2025;31:949\u201356.","journal-title":"Haemophilia"},{"key":"4231_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100176","volume":"7","author":"T Lissitchkov","year":"2023","unstructured":"Lissitchkov T, Willemze A, Jan C, Zilberstein M, Katragadda S. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa. Res Pract Thromb Haemost. 2023;7:100176.","journal-title":"Res Pract Thromb Haemost"},{"key":"4231_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/hae.70017","volume":"31","author":"R Klamroth","year":"2025","unstructured":"Klamroth R, von Drygalski A, Hermans C, Park YS, Chan AKC, Kupesiz A, et al. Perioperative management with efanesoctocog alfa in patients with haemophilia A in the phase 3 XTEND-1 and XTEND-Kids studies. Haemophilia. 2025;31:391\u2013400.","journal-title":"Haemophilia"},{"key":"4231_CR16","doi-asserted-by":"publisher","first-page":"3631","DOI":"10.1182\/blood-2004-03-1042","volume":"104","author":"A Tripodi","year":"2004","unstructured":"Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood. 2004;104:3631\u20134.","journal-title":"Blood"},{"key":"4231_CR17","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1111\/hae.14650","volume":"28","author":"Y Nakajima","year":"2022","unstructured":"Nakajima Y, Takami E, Nakano H, Nogami K. In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia\/X products (Byclot\u00ae ) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: a pilot study. Haemophilia. 2022;28:e149\u201352.","journal-title":"Haemophilia"},{"issue":"Suppl 77","key":"4231_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/ejh.12500","volume":"94","author":"JJ Potgieter","year":"2015","unstructured":"Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015;94(Suppl 77):38\u201344.","journal-title":"Eur J Haematol"},{"key":"4231_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/hae.14831","volume":"30","author":"S Pipe","year":"2024","unstructured":"Pipe S, Sadeghi-Khomami A, Konkle BA, Kitchen S, Negrier C, Liu M, et al. A global comparative field study to evaluate the factor VIII activity of efanesoctocog alfa by one-stage clotting and chromogenic substrate assays at clinical haemostasis laboratories. Haemophilia. 2024;30:214\u201323.","journal-title":"Haemophilia"},{"key":"4231_CR20","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.3390\/jcm11071969","volume":"11","author":"E Zanon","year":"2022","unstructured":"Zanon E, Pasca S, Demartis F, Tagliaferri A, Santoro C, Cantori I, et al. Intracranial Haemorrhage in Haemophilia Patients Is Still an Open Issue: The Final Results of the Italian EMO. REC Registry. J Clin Med. 2022;11:1969.","journal-title":"J Clin Med"},{"key":"4231_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s11239-022-02741-2","volume":"55","author":"B Tse","year":"2023","unstructured":"Tse B, Nisenbaum R, Floros G, Jiwajee A, Teitel J, Sholzberg M. Perioperative continuous infusions of factor VIII versus factor IX for patients with hemophilia A or B undergoing major surgery. J Thromb Thrombolysis. 2023;55:273\u201381.","journal-title":"J Thromb Thrombolysis"},{"key":"4231_CR22","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/ajh.27603","volume":"100","author":"AC Weyand","year":"2025","unstructured":"Weyand AC, Meunier S, Suzuki N, Bystrick\u00e1 L, Neill G, Abad-Franch L, et al. Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study. Am J Hematol. 2025;100:813\u201320.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04231-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04231-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04231-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:59:13Z","timestamp":1791194353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04231-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["4231"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04231-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K. has no disclosure of conflict of interest. Y.N. has received a grant from Takeda Pharmaceutical Co and KM Biologics Co. K.N. has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hoffmann-La Roche Ltd.; grants and personal fees from Sysmex Co., SEKISUI Medical, Takeda Pharmaceutical Co., Sanofi S. A., CSL Behring Co., KM Biologics Co., Novo Nordisk A\/S, Bayer AG, Fujimoto Seiyaku, Pfizer Inc.; and is an inventor of patents relating to emicizumab. K.N. is an editor of IJH.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}